Lundbeck strengthens its research capabilities by acquiring ground-breaking Danish technologies
- Details
- Category: Lundbeck
Through the acquisition of the Aarhus-based biotech company NeuronIcon, Lundbeck will gain ownership of technologies that may lead to a breakthrough in the treatment of brain damage following strokes or similar events. The acquisition is the result of Lundbeck's intensified collaboration with universities in Denmark and abroad.
Top 10 Tips for Staying Healthy When Money is Tight
- Details
- Category: Eli Lilly and Company
Several area health care organizations agree that today's tough economic times can make staying healthy a challenge. The organizations provided tips for Ohioans to stay healthy. Those organizations are: The Athletic Club of Columbus, Central Ohio Diabetes Association, Columbus Dietetic Association, Lilly USA, Mental Health America of Franklin County, NAMI Ohio, Ohio Association of Free Clinics, Ohio Department of Health and Prevent Blindness Ohio.
Phase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
- Details
- Category: Roche
Roche announced that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study.
GSK further extends its product portfolio in the Middle East and North Africa
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline plc (GSK) has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m).
Lu AA24530 shows positive results in major depressive disorder phase II study
- Details
- Category: Lundbeck
H. Lundbeck A/S (Lundbeck) today announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD).
Graceway Pharmaceuticals Acquires Early-stage Dermatological Molecules from Pfizer
- Details
- Category: Pfizer
Graceway Pharmaceuticals, LLC, a portfolio company of GTCR Golder Rauner, LLC, and Pfizer Inc. (NYSE: PFE) have entered into an Acquisition and License Agreement by which Graceway will acquire the worldwide commercial rights for three investigational dermatological molecules from Pfizer and the related transferred or licensed intellectual properties.
Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa
- Details
- Category: Clinical Trials
Schering-Plough Corp., (NYSE: SGP) has announced results from the Phase III ENGAGE clinical trial demonstrating that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, achieved similar efficacy to recombinant follicle stimulating hormone (rFSH) given once daily for seven days.
More Pharma News ...
- Bayer files patent infringement lawsuit against Teva
- IRESSA (Gefitinib) Receives Marketing Authorisation in Europe
- Pfizer Discontinues Phase 3 Trial of Sutent® in Metastatic Colorectal Cancer
- AstraZeneca Development Partner, Pozen, Inc., Submits New Drug Application for PN400
- Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
- Novo Nordisk reaches settlement with the Danish authorities regarding Oil-for-Food activities
- Lundbeck receives FDA Complete Response Letter on Serdolect® for the treatment of schizophrenia